Amarantus Bio Science
Biotechnology, 953 St, Sunnyvale, California, Indiana, 94107, United States, 1-10 Employees
Who is AMARANTUS BIOSCIENCE
Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan disea...
Read More
- Headquarters: 953 Indiana St, Sunnyvale, California, 94107, United States
- Date Founded: 2008
- Employees: 1-10
- Revenue: $5 Million to $10 Million
- Active Tech Stack: See technologies
- CEO: Gerald Commissiong
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from AMARANTUS BIOSCIENCE
Amarantus BioScience Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Amarantus BioScience
Answer: Amarantus BioScience's headquarters are located at 953 St, Sunnyvale, California, Indiana, 94107, United States
Answer: Amarantus BioScience's official website is https://amarantus.com
Answer: Amarantus BioScience's revenue is $5 Million to $10 Million
Answer: Amarantus BioScience's SIC: 2834
Answer: Amarantus BioScience has 1-10 employees
Answer: Amarantus BioScience is in Biotechnology
Answer: Amarantus BioScience contact info: Phone number: Website: https://amarantus.com
Answer: Amarantus BioScience Holdings (OTCQB: AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS owns the rights to Engineered Skin Substitute program, a regenerative medicine-based approach for treating severe burns with full thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army, and is also preparing a pivotal development program for rare pediatric disease Giant Congenital Melanocytic Nevi. AMBS' also has licensing rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuardTM) that led to MANF's discovery. Amarantus is a Founding Member of Global Brain Health Coalition (GBHC). The GBHC mission is to become the leading global voice for brain health awareness and empowerment by converging science, clinical research and impact. The Company believes that TBI-induced neurodegeneration represents a new frontier of clinical research which may ultimately allow for commonalities between chronic degenerative disorders.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month